Printer Friendly

PHOENIX LASER SYSTEMS INITIATES HUMAN CLINICAL TRIALS IN HONG KONG

PHOENIX LASER SYSTEMS INITIATES HUMAN CLINICAL TRIALS IN HONG KONG
 SAN FRANCISCO, May 1 /PRNewswire/ -- Phoenix Laser Systems, Inc., (AMEX: PNX) today announced that it has initiated Phase I clinical trials of the Phoenix Ophthalmic Laser Workstation at the Chinese University of Hong Kong, under the supervision of Patrick C.P. Ho. A total of eight laser procedures were performed on six patients, in the use of the Phoenix system on human patients for "corneal sculpting." The studies are being conducted in accordance with U.S. FDA protocols and the results of the studies will be submitted to FDA.
 Joann R. Schulz, Phoenix Laser Systems' president said, "We are extremely pleased with the results which have been achieved in the treatment of these first patients in Hong Kong. Intra-corneal lesions were successfully placed during all treatment sessions. Within an hour after treatment, the treatment areas had cleared and we were able to measure the effects of treatment. The patients found the procedure to be simple and painless and each of the procedures took only a few minutes to perform."
 Phoenix Laser Systems, Inc. is a developer of integrated laser workstations primarily for use by the medical community. The company's initial efforts have been focused on the design, development and testing of its first product, the Phoenix Ophthalmic Laser Workstation. The company's technology permits surgery designed to correct nearsightedness, farsightedness, and astigmatism, as well as a large number of eye disorders which are untreatable or only partially treatable with current technology.
 -0- 5/1/92
 /CONTACT: Michelle Coon or Jon Solow of Phoenix Laser Systems, 415-922-4061/
 (PNX) CO: Phoenix Laser Systems, Inc. ST: California IN: MTC SU:


TQ-OS -- NY024 -- 5372 05/01/92 10:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 1, 1992
Words:285
Previous Article:CSX APPOINTS PRESIDENT/CEO OF AMERICAN COMMERCIAL LINES
Next Article:SHELL OIL ANNOUNCES FIRST QUARTER EARNINGS


Related Articles
PHOENIX LASER SYSTEMS INC. SHIPS SURGICAL LASER WORKSTATION FOR GLAUCOMA TRIALS
PHOENIX LASER SYSTEMS INC. ANNOUNCES DR. J. JAMES ROWSEY, M.D., AS CORNEAL CONSULTANT
PHOENIX LASER SYSTEMS INC. ACQUIRES PATENT RIGHTS FOR SURGICAL LASER APPLICATIONS
PHOENIX LASER SYSTEMS, INC. RELEASES DATA FROM CLINICAL TESTING
PHOENIX LASER SYSTEMS, INC. SHIPS SURGICAL WORKSTATION TO UNIVERSITY OF SOUTH FLORIDA FOR ANIMAL AND CLINICAL TRIALS
PHOENIX LASER SYSTEMS, INC. APPOINTS DR. ROBERT DEL PERO AS RESEARCH ADVISOR
PHOENIX LASER SYSTEMS REACHES AGREEMENT WITH REFRACTIVE LASER RESEARCH
PHOENIX RELEASES SECOND QUARTER RESULTS AND ANNOUNCES RESIGNATION OF DIRECTOR
SUCCESSFUL SALE OF HONG KONG INVESTMENT
Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters